Alejandro López Targa Instituciones de las que forman parte Tècnic/a Grau Superior Unidad Internacional Dirección de Investigación Competitiva Vall Hebron Institut de Recerca Email Alejandro López Targa Email Instituciones de las que forman parte Tècnic/a Grau Superior Unidad Internacional Dirección de Investigación Competitiva Vall Hebron Institut de Recerca
Proyectos Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia IP: Rafael Simó Canonge Colaboradores: Marina Jimenez Iglesias, Cristina Hernández Pascual, Jaume Rigo Quera, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Queralt Martin Saladich, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Alejandro López Targa, Patricia Bogdanov Baruj, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Andreea Ciudin Mihai, Ferran Casals Riera Entidad financiadora: EUROPEAN COMMISSION Financiación: 950410 Referencia: RECOGNISED_H2020SC1BHC2019 Duración: 01/01/2020 - 31/12/2024 SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.. IP: SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.. Colaboradores: Marc Miquel Moltó Abad, Olga Sánchez- Maroto Carrizo, Julia German Cortes, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY-ENABLED MEDICAL TECHNOLOGIES FOR HEALTH.., Belen Garcia Prats, Angels Alcina Mila, Alejandro López Targa, Maria Fidel Lledò, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro Entidad financiadora: EUROPEAN COMMISSION Financiación: 649580 Referencia: SAFE-N-MEDTECHEC_H2020-NMBP2018 Duración: 01/04/2019 - 30/09/2023 Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease. GRANT AGREEMENT NO: 634579 IP: Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholi Colaboradores: Alejandro López Targa, Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholi Entidad financiadora: EUROPEAN COMMISSION Financiación: 93750 Referencia: CARBALIVE_H2020-PHC2014 Duración: 01/05/2015 - 31/01/2021 Paginación Primera página « Página anterior ‹ Página 1 Página actual 2
